MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Update

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 187,740 shares, a decline of 31.4% from the November 30th total of 273,552 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily volume of 194,579 shares, the short-interest ratio is presently 1.0 days. Based on an average daily volume of 194,579 shares, the short-interest ratio is presently 1.0 days. Currently, 0.5% of the shares of the company are short sold.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MIRA. First American Bank boosted its holdings in MIRA Pharmaceuticals by 150.0% in the 3rd quarter. First American Bank now owns 50,000 shares of the company’s stock valued at $68,000 after purchasing an additional 30,000 shares during the period. Two Sigma Investments LP grew its position in MIRA Pharmaceuticals by 129.8% during the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock worth $62,000 after buying an additional 25,816 shares in the last quarter. International Assets Investment Management LLC bought a new stake in MIRA Pharmaceuticals during the second quarter valued at approximately $42,000. Creative Planning purchased a new position in MIRA Pharmaceuticals in the 2nd quarter worth approximately $27,000. Finally, XTX Topco Ltd purchased a new position in MIRA Pharmaceuticals in the 2nd quarter worth approximately $26,000. Institutional investors own 35.16% of the company’s stock.

Analyst Ratings Changes

MIRA has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research note on Monday, December 22nd. Wall Street Zen lowered shares of MIRA Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

MIRA Pharmaceuticals Stock Down 2.0%

NASDAQ:MIRA traded down $0.03 on Monday, hitting $1.48. The stock had a trading volume of 171,078 shares, compared to its average volume of 249,107. The company has a market cap of $61.98 million, a PE ratio of -0.97 and a beta of 1.79. The business’s fifty day moving average is $1.49 and its 200 day moving average is $1.44. MIRA Pharmaceuticals has a 52 week low of $0.73 and a 52 week high of $2.45.

MIRA Pharmaceuticals (NASDAQ:MIRA) last announced its earnings results on Thursday, November 13th. The company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($0.11) by ($1.07). Equities analysts predict that MIRA Pharmaceuticals will post -0.6 earnings per share for the current fiscal year.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.